Nebido (Testosterone Undecanoate)

Testosterone undecanoate is a long‑acting ester of testosterone. After intramuscular injection, the ester is hydrolyzed, releasing testosterone that binds androgen receptors in target tissues. This receptor activation regulates gene expression involved in sexual development, muscle growth, bone density, and red blood cell production.

The specific dose and dosing interval of Nebido are determined by the prescribing clinician based on the patient’s clinical condition, baseline testosterone levels, and response to therapy. Physicians typically individualize the regimen; patients should follow the prescriber’s instructions without self‑adjusting the dose.

Nebido is not intended for use in women, and its safety in pregnancy or lactation has not been established. The product is classified for male hormone replacement, and it should be avoided in pregnant or nursing women. If exposure occurs, medical advice should be sought promptly.

To order Nebido, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

Nebido provides a long‑acting intramuscular formulation that requires dosing every 10‑12 weeks, reducing injection frequency compared with shorter‑acting esters such as testosterone enanthate or cypionate. Transdermal gels and patches offer daily administration but may cause skin irritation. Choice of product depends on patient preference, adherence considerations, and clinical response.

Nebido should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. If temporary storage at room temperature is unavoidable, limit exposure to less than 30 °C for a short period and return the product to refrigeration promptly.

Nebido is administered as a deep intramuscular injection, typically into the gluteal muscle. The injection is performed by a qualified healthcare professional using aseptic technique. The volume is 4 mL containing 1000 mg of testosterone undecanoate, and the dosing schedule is set by the prescriber.

Serious risks include polycythemia (elevated red blood cell count), which can increase clotting risk; cardiovascular events such as myocardial infarction or stroke; and potential exacerbation of prostate disease. Patients should be monitored regularly for hematocrit, cardiovascular status, and prostate health throughout therapy.

Nebido is contraindicated in individuals with known hypersensitivity to testosterone undecanoate, in patients with active prostate or breast cancer, in those with severe untreated sleep‑apnea, and in men with uncontrolled cardiovascular disease. It should also be avoided in women and children, as the product is intended for male hormone replacement.